Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations.
about
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.CNS Erdheim-Chester Disease: A Challenge to Diagnose.Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibitionHistiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016
P2860
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Trametinib after disease react ...... both BRAF and KRAS mutations.
@en
Trametinib after disease react ...... both BRAF and KRAS mutations.
@nl
type
label
Trametinib after disease react ...... both BRAF and KRAS mutations.
@en
Trametinib after disease react ...... both BRAF and KRAS mutations.
@nl
prefLabel
Trametinib after disease react ...... both BRAF and KRAS mutations.
@en
Trametinib after disease react ...... both BRAF and KRAS mutations.
@nl
P2093
P50
P1433
P1476
Trametinib after disease react ...... both BRAF and KRAS mutations.
@en
P2093
Aino Paasinen-Sohns
Christoph T Berger
Gieri Cathomas
Thierry M Nordmann
Thomas Daikeler
P304
P356
10.1182/BLOOD-2016-09-740217
P407
P577
2016-12-09T00:00:00Z